Spero Therapeutics Inc (SPRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $58.26M
Last updated: Nov 17, 2026 at 4:11 PM ET
Spero Therapeutics Inc (SPRO) Stock Chart
Spero Therapeutics (SPRO) has a latest price of $0.90 on Nov 17, 2026, 70.7% below its 52-week high of $3.08. Its price fell 62.6% over the past 12 months. The month-end price fell 91.1% since Nov 2017, a compound annual decline of 23.8%.
Price Chart
From Nov 2017 to Oct 2026, its highest month-end close was $19.39 in Dec 2020 and its lowest $0.66 in Apr 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart SPRO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for SPRO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 26.7%, and over 6 months it fell 65.2%. The month-end price fell 1.9% over the 3 years through Oct 2026, a compound annual decline of 0.6%.
| Period | Change |
|---|---|
| 1 month | -19.5% |
| 3 months | -26.7% |
| 6 months | -65.2% |
| 12 months | -62.6% |
| 12 months, with dividends | -62.6% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -1.9% | -0.6% |
| 5 years | -94.0% | -43.0% |
| Since Nov 2017 | -91.1% | -23.8% |
Price by Year
Its best calendar year was 2025, when the price rose 126.2%, and its weakest was 2022, when it fell 89.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.06 | -54.5% |
| 2025 | $2.33 | +126.2% |
| 2024 | $1.03 | -29.9% |
| 2023 | $1.47 | -15.0% |
| 2022 | $1.73 | -89.2% |
| 2021 | $16.01 | -17.4% |
| 2020 | $19.39 | +101.7% |
| 2019 | $9.62 | +56.3% |
| 2018 | $6.15 | -47.7% |
Trading Range
The price is 20.0% below its 50-day average of $1.13 and 52.6% below its 200-day average of $1.90.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.90 | |
| 52-week high | $3.08 | -70.7% |
| 52-week low | $0.90 | +0.1% |
| 50-day average | $1.13 | -20.0% |
| 200-day average | $1.90 | -52.6% |
Price Risk
Over 3 years, its largest fall from a peak was 70.4%.
| Measure | Value |
|---|---|
| 1-year beta | 1.53 |
| Largest fall, 1 year | -69.8% |
| Largest fall, 3 years | -70.4% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About SPRO
What is SPRO's 1-year price change?
Spero Therapeutics's price fell 62.6% over the past 12 months. With dividends included, the 12-month total return was -62.6%.
What is SPRO's 5-year price change?
Spero Therapeutics's month-end price fell 94.0% over the 5 years through Oct 2026, a compound annual decline of 43.0%. These figures leave out dividends.
What is SPRO's 52-week high and low?
Spero Therapeutics's 52-week high is $3.08 and its 52-week low is $0.90. Its latest price of $0.90 on Nov 17, 2026 is 70.7% below the high.
What is SPRO's beta?
Spero Therapeutics's 1-year beta against the S&P 500 is 1.53, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 69.8%.
Is the SPRO chart free?
Yes. Advanced Charting for SPRO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
SPRO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts